

National Cancer Institute
Institutional Review Board

AGENDA

March 23, 2015

1:00 – 5:00 pm

10 CRC/3-1608

1. Review of Draft Minutes, March 9, 2015

2. Announcements

3. Old Business

- Progress Report for Dr. Kreitman's Protocols

4. New Business

- NCI Consent Form Template

5. Problem Report Forms

6. Other Expedited Actions

7. Continuing Reviews

- 8. Amendment** 02C0077-N, "Characterization of High Risk Breast Duct Epithelium by Cytology, Breast Duct Endoscopy, and cDNA Gene Expression Profile" - David Danforth, PI

- 9. Amendment** 09C0025-N, "Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia" - Robert Kreitman, PI

- 10. Amendment** 10C0114-K, "A Phase II Study of Bevacizumab and Erlotinib in Subjects with Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer" - Ramaprasad Srinivasan, PI

- 11. Initial Review** P141760, "A Phase 1 Study of Subcutaneous Recombinant Human hetIL-15 (IL15 / sIL-15Ra) in Adults with Metastatic Cancers" - Kevin Conlon, PI

- 12. Initial Review** P141998, "Clinical Sequencing of Cancer and Tissue Repository" - Javed Khan, PI

- 13. Initial Review** P141739, "A Phase II Study of the Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015, HA22) in Children with B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation" - Nirali Shah, PI